A new direct oral anticoagulant APIXA (apixaban) in tablets of 5 mg and 2.5 mg has shown up in Belarusian pharmacies. Until recently, the promising class of direct oral anticoagulants was represented in our country only by dabigatran and rivaroxaban products, while original and generic apixaban was not available. APIXA, the first apixaban generic, forthcoming was possible due to cooperation with our Indian partner, Natco Pharma Ltd. Bioequivalence of APIXA to the original apixaban according to the FDA criteria was confirmed in a clinical study conducted in the United States and Canada. The results of this study were presented in the registration dossier.

The NatiVita’s solid dosage forms production area was certified to comply with the rules of the Pharmaceutical Inspection Convention and the Pharmaceutical Inspection Cooperation Scheme (PIC/S).

The medical department of NatiVita has prepared a scientific review “How to optimize trastuzumab adjuvant treatment of early-stage HER2-positive breast cancer”, which was published in the leading Belarusian professional publication in the field of oncology “Oncological Journal” (Oncological Journal 2020; 14(2-3): 131-140).

Head of Clinical Research Department NatiVita company Natalia Murashko will prepare a report at the practical forum “Clinical Research in the EAEU” on June in Moscow.

NatiVita supported an open day organized by the public Association of disabled people “The assistance to patients with multiple sclerosis”.

On December 21 In Vitebsk was held the SOFT FEST festival, the final event of the 2019 TALENAVITA program, which was attended by more than a hundred high school students and students.

On December 23th the results of the Republican contest of innovative projects were summed up in Minsk and was announced the winner of the special nomination of NatiVita “Biotechnologies and genomics in medicine and pharmaceuticals”.

For ten days in the Vitebsk region in Lepel township 25 students developed research projects on the theme “ABOUT health: Biotechnology for quality of life”. During the summer science camp boys and girls had to meet and talk to experts from 18 universities of Belarus, national Academy of Sciences of Belarus and leading scientific-practical medical centers.

For the second year in a row, NatiVita supports the Republican competition of innovative projects and announces its own nomination with a prize Fund of two thousand dollars.

With the support of NatiVita, the national team of Belarus in beach football visited the Republican scientific and practical center of pediatric Oncology, Hematology and immunology. Before the start of the competition at the II European games, the athletes supported the guys who are fighting cancer and played football with them.

NatiVita company opens the reception of applications for the summer scientific camp TALENAVITA CAMP 2019, which will be held within the framework of the Republican program to support talented young people TALENAVITA.

NATIVITA summarized the results of the next stage of transfer of manufacturing technologies in the presence of shareholders and honored guests, representatives of the diplomatic mission in the Republic of Belarus.

On the 17th April Alexander Turchin, first Vice Prime Minister of the Republic of Belarus, visited NATIVITA scientific and manufacturing complex.

The joint Commission of the National Academy of Sciences and the State Committee of science and technology of the Republic of Belarus awarded NatiVita the status of a scientific organization.

From 8th to 14th April with the support of NatiVita will be held the full-time stage of the scientific and educational project Sciteen that is conscript to involve students in solving applied tasks and developing innovative projects. Our company became the official partner of the event.

On December 26^th the results of the 9^th National Contest of Innovational projects were announced in Minsk where they named a winner of the special nomination by NatiVita called “Biotechnology and genomics in medicine and pharmaceuticals”.

On the 30 of August the inspection of the Ministry of Health of the Republic of Iraq has visited the manufacturing complex of NatiVita

NatiVita has registered the first medicinal products in the Republic of Moldova. In the near future, two drugs will immediately receive registration certificates: T-Mab (Trastuzumab) and B-Mab (Bevacizumab). T-Mab and B-Mab are the first drugs registered by NatiVita outside Belarus.

On the 25 of September, NatiVita took part in the first meeting of the Belarusian-Slovak Commission for Cooperation in Science and Technology in Minsk.

NatiVita team took part in the semi-marathon, which was held for the fourth time in Minsk. 

Representatives of NatiVita took part in the 6th meeting of the Uzbek-Belarusian intergovernmental commission for bilateral cooperation

Drug for multiple sclerosis treatment

• NatiVita has been granted with a product license for generic drug Glatiramer acetate brand named GLACETAT.

NatiVita became a partner of Ride4Women charity bike ride

On Sunday, July 8th, NatiVita team took part in Ride4Women charity bike ride, which goal was to attract attention to women’s health problems and inform as many people as possible that cancer could be prevented and cured.

On Saturday, July 28, the expert council of the TALENAVITA program selected the best project in the scientific session of TALENAVITA CAMP. The team-winner offered the jury a simple and potentially effective respiratory test for screening the stomach cancer.

Belarusian students will seek solutions to oncology problems in the scientific camp TALENAVITA CAMP

NatiVita became a partner of Ride4Women charity bike ride.

This Sunday, on July 8th Ride4Women charity bike ride dedicated to treatment of oncological diseases will be held supported by NatiVita.